Immunotherapy in Ovarian Cancer

Weimin Wang; Janice Rebecca Liu; Weiping Zou

doi:10.1016/j.soc.2019.02.002

Immunotherapy in Ovarian Cancer

Surg Oncol Clin N Am. 2019 Jul;28(3):447-464. doi: 10.1016/j.soc.2019.02.002. Epub 2019 Apr 5.

Authors

Weimin Wang¹, Janice Rebecca Liu², Weiping Zou³

Affiliations

¹ Department of Surgery, University of Michigan School of Medicine, BSRB 5448, 109 Zina Pitcher Place, Ann Arbor, MI 48109-0669, USA.
² Department of Obstetrics and Gynecology, University of Michigan School of Medicine, L4604 WH, 1500 East Medical Center, Ann Arbor, MI 48109, USA.
³ Department of Surgery, University of Michigan School of Medicine, BSRB 5071, 109 Zina Pitcher Place, Ann Arbor, MI 48109-0669, USA. Electronic address: wzou@med.umich.edu.

Abstract

The phenotype and functionalities of the major immune cell subsets including myeloid cells, macrophages, dendritic cells, and T cells are altered in the ovarian cancer microenvironment. Immunosuppressive networks including inhibitory B7 family members and regulatory T cell-associated adenosine pathway have been defined in human ovarian cancer. In this review, the authors integrate emerging information on immunosuppressive mechanisms and T cell phenotype and discuss strategies of immunotherapeutic and vaccine regimens. Finally, crucial points regarding design of immuno-oncology clinical trials are reviewed.

Keywords: Adoptive T-cell transfer; Cancer vaccine; Checkpoint blockade; Immunotherapy; Ovarian cancer.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
Cancer Vaccines / therapeutic use*
Female
Humans
Immunotherapy / methods*
Ovarian Neoplasms / immunology
Ovarian Neoplasms / therapy*
T-Lymphocytes / immunology*
Tumor Microenvironment / immunology*

Substances

Antibodies, Monoclonal
Cancer Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding